Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Free Report)’s stock price reached a new 52-week high on Monday . The stock traded as high as $51.25 and last traded at $49.73, with a volume of 159339 shares traded. The stock had previously closed at $49.41.
Gemini Therapeutics Stock Up 0.6 %
The stock’s 50 day moving average price is $45.34 and its 200-day moving average price is $45.44. The stock has a market capitalization of $2.15 billion, a PE ratio of -1.35 and a beta of -0.12.
Gemini Therapeutics Company Profile
Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.
See Also
- Five stocks we like better than Gemini Therapeutics
- How to Start Investing in Real Estate
- Why the Buy-and-Hold Strategy May Be Best for Most Investors
- Election Stocks: How Elections Affect the Stock Market
- Eli Lilly’s Path to the Next Trillion Market Capitalization
- Insider Buying Explained: What Investors Need to Know
- Mobileye Global: CEO Makes $10 Million Bet on Future Strength
Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
